Cyclacel is a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious diseases. The Company has three orally-available product candidates in clinical development, for which Cyclacel has retained rights in most global markets. Through Cyclacel’s ALIGN Pharmaceuticals subsidiary, the Company markets Xclair® Cream for radiation dermatitis, Numoisyn® Liquid and Numoisyn® Lozenges for xerostomia in the United States. Cyclacel’s strategy is to build a diversified biopharmaceutical business focused in hematology and oncology based on a portfolio of commercial products and a development pipeline of novel drug candidates.
Follow MD Becker Partners